Bionano Genomics (BNGO) Depreciation & Amortization (CF) (2017 - 2026)

Bionano Genomics has disclosed Depreciation & Amortization (CF) across 10 years of filings, most recently posting $2.3 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $2.3 million, down 5.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.2 million (down 12.62% YoY), and the FY2025 annual result was $9.5 million, down 32.06% from the prior year.
• Depreciation & Amortization (CF) came in at $2.3 million for Q1 2026 at Bionano Genomics, down from $2.3 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.6 million in Q3 2023 to a low of $1.8 million in Q3 2025.
• The 5-year median for Depreciation & Amortization (CF) is $2.4 million (2022), against an average of $2.6 million.
• Across the five-year window, Depreciation & Amortization (CF) surged 393.3% in 2022 and plunged 36.74% in 2024, its largest moves.
• Bionano Genomics' Depreciation & Amortization (CF) stood at $2.8 million in 2022, then surged by 30.01% to $3.6 million in 2023, then sank by 33.31% to $2.4 million in 2024, then dropped by 2.54% to $2.3 million in 2025, then dropped by 1.16% to $2.3 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $2.3 million (Q1 2026), $2.3 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.